The company
Gyre Therapeutics, Inc.
GYRE · Nasdaq
GYRE stood above a rising 150-day average in 4 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 9.9% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 32
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $1.9M
- Officials’ trades on record
- 0
- Institutions holding
- 59 (+6)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 4 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Weiguo YeChief Operating Officer | sold | 3,000at $6.35 | 18 Jun 2026filed 22 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 2,800at $6.17 | 11 Jun 2026filed 15 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 6,418at $6.21 | 10 Jun 2026filed 11 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 5,000at $6.24 | 10 Jun 2026filed 22 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 14,500at $6.14 | 9 Jun 2026filed 11 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 3,000at $6.15 | 9 Jun 2026filed 22 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 15,401at $6.40 | 5 Jun 2026filed 8 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 19,575at $6.13 | 4 Jun 2026filed 8 Jun 2026 |
| Weiguo YeChief Operating Officer | sold | 4,000at $6.10 | 26 May 2026filed 27 May 2026 |
| Weiguo YeChief Operating Officer | sold | 3,500at $6.08 | 22 May 2026filed 27 May 2026 |
| Weiguo YeChief Operating Officer | sold | 12,820at $6.15 | 21 May 2026filed 22 May 2026 |
| Weiguo YeChief Operating Officer | sold | 9,400at $6.15 | 20 May 2026filed 22 May 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| HSG Holding Ltdnew · filed 13 Aug 2026 | 3,750,299$24.7M | +3,750,299 |
| BlackRock, Inc.added · filed 7 Aug 2026 | 993,943$6.6M | +235,313+31.0% |
| Octagon Capital Advisors LPnew · filed 14 Aug 2026 | 954,416$6.3M | +954,416 |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 876,927$5.8M | -107,277−10.9% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 532,950$3.5M | +101,536+23.5% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 245,402$1.6M | +29,076+13.4% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INCadded · filed 14 Aug 2026 | 184,286$1.2M | +19,048+11.5% |
| Sixth Street Partners Management Company, L.P.new · filed 14 Aug 2026 | 184,286$1.2M | +184,286 |
| NORTHERN TRUST CORPadded · filed 13 Aug 2026 | 169,537$1.1M | +35,696+26.7% |
| SBI Securities Co., Ltd.reduced · filed 23 Jul 2026 | 166,750$1.1M | -4,087−2.4% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.